January 20, 2009: PDS Biotechnology Corp., which develops nanoparticle-based anti-cancer agents, is moving from its Cincinnati birthplace to Indianapolis, according to a report in the Business Courier of Cincinnati.
The company, which began at Cincinnati’s BioStart incubator, also received a $2 million grant from the Indiana 21st Century Research and Technology Fund. The paper said the National Cancer Institute’s Nanotechnology Characterization Lab announced a collaboration with the company in November to develop PDS’s patented Versamune nanoparticle technology.
The company has not yet announced where in Indianapolis it will relocate.